Sustained release excipients Market

The market CAGR for sustained release excipients is expected to grow in the future due to the increasing incidence of both acute and chronic diseases. Diseases are classified into two main categories based on their duration and progression - acute and chronic diseases or such prolonged periods. Acute diseases are usually characterized by rapid onset of severe but transient symptoms. The duration of these illnesses is usually short—hours, days, or weeks—and they arise suddenly. Adjuvants with long-lasting diuretics are often used to treat acute and chronic problems.

These features increase sales of adjuvants that maintain consistency, even maintain dosage levels, reduce side effects, and promote patient adherence and disease management well. NCD) Most deaths—approximately 17.9 million annually—are due to cardiovascular diseases, followed by chronic respiratory diseases (4.1 million), diabetes (2 million, including diabetic kidney disease), and cancer (9.3 million) by October 2022. U.S.-based A statement by the Pan American Health Organization, an international public health organization, documented that 10.6 million individuals will be infected with tuberculosis (TB) by 2021, up 4.5% from 2020.

Thus, there is a market for extracted support that has a long history of severe and chronic increases due to mounting problems.

Going forward, the market for sustained release excipients is anticipated to rise at a rapid pace due to the increasing need for personalized medication. Medical practitioners use precision medicine to deliver and plan individualized care by analyzing each patient's distinct genes, proteins, and other body parts. This approach is known as personalized medicine or personalized care. Sustained-release excipients are essential to personalized medicine because they make it possible to create medication formulations that are specific to each patient's needs.

For instance, about one-third of all newly authorized therapeutic molecular entities were approved by the US Food and Drug Administration (FDA) in 2022, with 12 of those medications being personalized. Based on a paper from the US-based professional membership organization Personalized Medicine Coalition titled The Scope and Significance of Progress in 2022, this information has been compiled. Thus, the market for sustained release excipients is expanding due to the rising need for individualized treatment. Thus, driving the sustained release excipients market revenue.

The Global Sustained Release Excipients Market Industry is poised for substantial growth, with projections indicating a market size of 1.5 USD Billion in 2024 and an anticipated increase to 3.15 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 6.98% from 2025 to 2035. Such figures reflect the increasing adoption of sustained release technologies across various therapeutic areas, driven by factors such as rising chronic disease prevalence and advancements in drug delivery systems. The market's expansion is indicative of a broader trend towards innovative pharmaceutical solutions that enhance patient outcomes.

The Global Sustained Release Excipients Market Industry is significantly influenced by the rising geriatric population, which is more susceptible to chronic illnesses requiring long-term medication. As individuals age, their healthcare needs evolve, leading to an increased demand for sustained release formulations that offer convenience and improved adherence to treatment regimens. According to demographic studies, the global population aged 65 and older is projected to double by 2050, creating a substantial market opportunity. This demographic shift necessitates the development of tailored drug delivery systems, thereby driving the growth of the sustained release excipients market.

The Global Sustained Release Excipients Market Industry is witnessing a shift towards personalized medicine, which emphasizes tailored treatment approaches based on individual patient profiles. This trend is driving the demand for sustained release formulations that can be customized to meet specific therapeutic needs. Pharmaceutical companies are increasingly leveraging data analytics and genetic profiling to develop personalized drug delivery systems, enhancing treatment efficacy. As the healthcare landscape evolves, this focus on personalized medicine is expected to propel market growth, aligning with the broader trend of individualized healthcare solutions.

The Global Sustained Release Excipients Market Industry experiences a notable increase in demand for controlled release formulations. These formulations are preferred for their ability to maintain therapeutic drug levels over extended periods, thereby enhancing patient compliance. For instance, the market is projected to reach 1.5 USD Billion in 2024, driven by the rising prevalence of chronic diseases that necessitate long-term medication regimens. Pharmaceutical companies are increasingly investing in research and development to innovate sustained release technologies, which further propels market growth. This trend indicates a shift towards more patient-centric approaches in drug delivery systems.

Technological advancements play a crucial role in shaping the Global Sustained Release Excipients Market Industry. Innovations in polymer science and nanotechnology have led to the development of novel excipients that enhance the efficacy and stability of sustained release formulations. For example, the introduction of biodegradable polymers has enabled the creation of environmentally friendly excipients that meet regulatory standards. These advancements not only improve drug release profiles but also reduce side effects, making medications safer for patients. As a result, the market is expected to grow significantly, with projections indicating a rise to 3.15 USD Billion by 2035.

Regulatory bodies worldwide are increasingly supportive of advanced drug delivery technologies, which positively impacts the Global Sustained Release Excipients Market Industry. Initiatives aimed at expediting the approval process for innovative drug formulations encourage pharmaceutical companies to invest in sustained release technologies. For instance, the U.S. Food and Drug Administration has established guidelines that facilitate the development of complex drug delivery systems. This regulatory support not only fosters innovation but also enhances market accessibility for new products, thereby contributing to the projected CAGR of 6.98% for the period from 2025 to 2035.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American sustained release excipients market area will dominate this market. Increased R&D efforts and the presence of significant pharmaceutical businesses in the area are credited with the region's success. Over the course of the forecast period, the region is expected to become more profitable due to patent expirations and the subsequent arrival of generics.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: SUSTAINED RELEASE EXCIPIENTS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe sustained release excipients market accounts for the second-largest market share. The primary driver of market expansion is the aging population. Furthermore, it is projected that the advancement of complex biologics and the growing need for novel drug delivery systems will drive market growth in this sector. Further, the German sustained release excipients market held the largest market share, and the UK sustained release excipients market was the fastest growing market in the European region.

The Asia-Pacific Sustained Release Excipients Market is expected to grow at the fastest CAGR from 2024 to 2032. The increased incidence of numerous infectious diseases, the quickly expanding healthcare system, and the growing need for highly potent medications are all factors contributing to this region's rise. Moreover, China’s sustained release excipients market held the largest market share, and the Indian sustained release excipients market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the sustained release excipients market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the sustained release excipients industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global sustained release excipients industry to benefit clients and increase the market sector. In recent years, the sustained release excipients industry has offered some of the most significant advantages to medicine. Major players in the sustained release excipients market are attempting to increase market demand by investing in research and development operations, including Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, Mayne Pharma Group Limited, Mylan NV, Novartis AG, Pfizer Inc., Salix Pharmaceuticals, and Sun Pharmaceutical Industries Ltd.

As a division of AbbVie Inc., Allergan Ltd. (Allergan) is a specialty pharmaceutical business that creates and distributes over-the-counter (OTC) and branded medications as well as biosimilars. The company sells goods in the following therapeutic categories: anti-infective, urology, women's health, dermatology, central nervous system, eye care, and gastroenterology. Its clients include mail-order merchants, hospitals, clinics, government agencies, and managed healthcare providers, including health maintenance organizations and other institutions. It also distributes its products to retailers, drug wholesalers, and distributors, including national retail medicine and grocery store chains.

Biopharmaceuticals are discovered, developed, produced, and marketed by Pfizer Inc. (Pfizer). The company offers solutions to address a variety of conditions, such as those related to women's health, cancer, inflammatory diseases, immune system issues, and metabolic, cardiovascular, and pain disorders. Additionally provided are sterile injectable drugs, biosimilars, contract manufacturing services, and active pharmaceutical ingredients (APIs). For over $6.7 billion, US-based pharmaceutical and biotechnology company Pfizer Inc. purchased Arena Pharmaceuticals in December 2021.

The purchase of Arena bolsters Pfizer's capabilities and expertise in immunology and inflammation, a Pfizer innovation engine that develops effective therapies for patients with debilitating immuno-inflammatory diseases in need of new treatment options.